Status:
RECRUITING
Immune Modulation by Exosomes in COVID-19
Lead Sponsor:
University of Ulm
Conditions:
COVID-19
Critical Illness
Eligibility:
All Genders
18-90 years
Brief Summary
Following whole blood stimulation with mesenchymal stem cell derived exosomes, immune phenotype, cytokine release and mRNA expression patterns from critically ill patients with COVID-19 will be determ...
Detailed Description
Critically ill patients with COVID-19 may develop lung failure and require extracorporal oxygenation due to hyperinflammation and progressive lung fibrosis. The anti-inflammatory and immune modulatory...
Eligibility Criteria
Inclusion
- Critically ill COVID-19 patients with lung dysfunction
- COVID-19 WHO severity degree \>= 4, ARDS (WHO Definition 13 March 2020)
- Body weight \> 50 kg
- Informed consent
Exclusion
- Pregnant or breast feeding women
Key Trial Info
Start Date :
December 22 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT05191381
Start Date
December 22 2021
End Date
December 31 2026
Last Update
January 17 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ulm University Hospital, Clinic of Anesthesiology and Intensive Care Medicine
Ulm, Germany, 89070